On the role of CNTF as a potential therapy for retinal degeneration: Dr. Jekyll or Mr. Hyde?
Beltran
William A
WA
Section of Ophthalmology, Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. wbeltran@vet.upenn.edu
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D020934:Ciliary Neurotrophic Factor / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004596:Electroretinography; D006801:Humans; D008268:Macular Degeneration / Q000473:pathology / Q000628:therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009755:Night Blindness / Q000235:genetics / Q000628:therapy / Q000662:veterinary*; D010786:Photoreceptor Cells / Q000187:drug effects; D012160:Retina / Q000187:drug effects; D012162:Retinal Degeneration / Q000188:drug therapy* / Q000235:genetics
D020934:Ciliary Neurotrophic Factor; D018696:Neuroprotective Agents